Richard Buchholz - 09 Jan 2026 Form 3 Insider Report for Inspire Medical Systems, Inc. (INSP)

Role
Interim CFO
Signature
/s/ Bryan Phillips, Attorney-in-Fact for Richard Buchholz
Issuer symbol
INSP
Transactions as of
09 Jan 2026
Net transactions value
$0
Form type
3
Filing time
11 Feb 2026, 17:15:40 UTC
Previous filing
02 Sep 2025
Next filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Buchholz Richard Interim CFO C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BLVD., SUITE 1600, GOLDEN VALLEY /s/ Bryan Phillips, Attorney-in-Fact for Richard Buchholz 11 Feb 2026 0001737133

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding INSP Common Stock 44,567 09 Jan 2026 Direct F1
holding INSP Common Stock 1,475 09 Jan 2026 By Son
holding INSP Common Stock 1,475 09 Jan 2026 By Son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding INSP Employee Stock Option (Right to Buy) 09 Jan 2026 Common Stock 4,376 $194.87 Direct F2
holding INSP Employee Stock Option (Right to Buy) 09 Jan 2026 Common Stock 5,450 $263.16 Direct F3
holding INSP Employee Stock Option (Right to Buy) 09 Jan 2026 Common Stock 5,924 $227.53 Direct F4
holding INSP Employee Stock Option (Right to Buy) 09 Jan 2026 Common Stock 17,300 $194.82 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 5,974 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs will vest in accordance with the terms of the underlying awards.
F2 The option vested and became exercisable as to 25% of the underlying shares on February 9, 2025. The remaining 75% of the underlying shares will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F3 The option vested and became exercisable as to 25% of the underlying shares on February 10, 2024. The remaining 75% of the underlying shares will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F4 The option is fully vested and exercisable.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney.